Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 14, 2023--
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 14, 2023--